Pharmaceutical CDMO Market Size | Industry Trends & Growth Insights 2025

Q: How does 6W market outlook report help businesses in making decisions?

6W monitors the market across 60+ countries Globally, publishing an annual market outlook report that analyses trends, key drivers, Size, Volume, Revenue, opportunities, and market segments. This report offers comprehensive insights, helping businesses understand market dynamics and make informed decisions.

Q: Do you also provide customisation in the market study?

Yes, we provide customisation as per your requirements. To learn more, feel free to contact us on sales@6wresearch.com

Code: MTA10301

Publication Date: Oct 2025

What is the size of Pharmaceutical CDMO Market?

According to 6Wresearch internal database and industry insights, the Global Pharmaceutical CDMO Market was valued at USD 120 Billion in 2024 and is expected to reach USD 182.5 Billion by 2031, growing at a compound annual growth rate of 5% during the forecast period (2025-2031).

The main drivers of this growth are the rising outsourcing of drug development and manufacturing services, increasing complexity of therapeutic pipelines requiring specialist contract partners, and the expanding need for capacity and expertise in biologics, small-molecules and formulation manufacturing.

View Main Report

Schedule Analyst Call

Growth Factors for Pharmaceutical CDMO Industry

Growing interest in outsourcing development and manufacturing as companies focus on core competencies.
Demand for contract services is being driven by the rising volume and complexity of biologics and advanced therapeutics.
Popularity among pharma companies due to its positive effects on cost-efficiency and time-to-market.
Expansion of online sourcing and global supply-chain partnerships for contract manufacturing services.
Innovation in integrated end-to-end CDMO service models and facility expansions.

Pharmaceutical CDMO Market Trends

Trends in the Pharmaceutical CDMO Market include an increase in demand for one-stop contract development and manufacturing organisations (CDMO) with workflows that include API, formulation and fill/finish. Providers are in the process of expanding capacity in biologics, cell & gene therapies and advanced dosage forms. In addition, lean manufacturing, digitalised operations, and flexible modular facilities are gaining momentum while companies partner and invest in capacity to accommodate increasing demand for contract development and manufacturing capabilities.

Emerging Developments in the Pharmaceutical CDMO Market

Developments in the Pharmaceutical CDMO Market include increased capital investment in dedicated facilities for cell, gene and viral vector manufacturing, as well as expansions of sterile injectables and high-potency APIs. Service providers are launching integrated platforms and strategic partnerships to provide turnkey solutions that start at early-phased development and progress through to commercial manufacturing. Additionally, under global supply-chain diversification and regulatory pressure, CDMOs are exploring multi-region footprints and innovations in digital manufacturing.